The role of short course of high-dose methylprednisolone in children with acute myeloblastic leukemia (FAB M2) presented with myeloid tumor

Hicsonmez G., Cetin M., Aslan D., Ozyurek E.

PEDIATRIC HEMATOLOGY AND ONCOLOGY, cilt.20, sa.5, ss.373-379, 2003 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20 Sayı: 5
  • Basım Tarihi: 2003
  • Doi Numarası: 10.1080/08880010390203954
  • Dergi Adı: PEDIATRIC HEMATOLOGY AND ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.373-379
  • Anahtar Kelimeler: acute myeloblastic leukemia, children, high-dose methylprednisolone, myeloid tumor, ACUTE LYMPHOBLASTIC-LEUKEMIA, PEDIATRIC-ONCOLOGY-GROUP, MYELODYSPLASTIC SYNDROME, GRANULOCYTIC SARCOMA, DIFFERENTIATION, CELLS, REMISSION, EXPRESSION, INDUCTION, SENSITIVITY
  • Gazi Üniversitesi Adresli: Evet

Özet

The authors have previously demonstrated a favorable effect of high-dose methylprednisolone (HDMP), which can induce differentiation and apoptosis of leukemic cells in children with acute myeloblastic leukemia (AML). Here, they evaluate the effect of short-course HDMP in 2 children with acute myeloblastic leukemia (AML-M2) presented with myeloid tumor (MT). Methylprednisolone (20 or 30 mg/kg/day) was given orally, in a single dose, without using other antileukemic agents. Rapid cytoreduction in MT, peripheral blood, and bone marrow blasts was observed in both children following short-course (4 or 7 days) HDMP treatment, possibly due to HDMP-induced differentiation and apoptosis of leukemic cells. The effects of HDMP should be explored in patients with other subtypes of AML who present with MT.